Actinium-225 (Ac-225) Radiopharmaceutical Market Size, Trends & Growth Opportunity By Production Method (Thorium-229 Extraction, Accelerator-Based, Cyclotron, Reactor-Assisted), By Product Offering (Radioisotope Supply, Radiopharmaceutical Intermediates, Contract Manufacturing Support), By Therapeutic Application (Prostate Cancer, Neuroendocrine Tumors, Leukemia, Lymphoma, Solid Tumors), By End User (Radiopharmaceutical Manufacturers, Biotechnology Companies, Academic Medical Centers), By Region and Forecast Till 2030

Report ID : AMR1005756 | Industries : Healthcare | Published On :July 2026 | Page Count : 277

Request Sample
Ask for Customization

Therapy Market

The global Actinium-225 radiopharmaceutical supply and targeted alpha therapy market is valued at USD 685 million in 2025 and is projected to reach USD 1,540 million by 2030, expanding at a compound annual growth rate of 17.6% across the forecast period. Growth is anchored in a structural supply-demand imbalance: clinical demand for alpha-emitting radioconjugates is scaling faster than the world's Thorium-229 extraction and accelerator-based production capacity can currently support.

This dual dynamic, chronic upstream scarcity paired with accelerating downstream clinical adoption, is what separates Ac-225 from most other oncology-adjacent markets. Isotope producers hold genuine pricing power, while radiopharmaceutical developers are racing to secure long-term supply commitments years ahead of anticipated commercial launches. Our analysis identifies three structural shifts reshaping how supply contracts, clinical development timelines, and regional manufacturing investment are converging around this single isotope.

Market Overview & Definition

Actinium-225 is a high-linear-energy-transfer, alpha-emitting radionuclide used to label targeting vectors, primarily monoclonal antibodies and small peptides, that deliver localized, DNA-damaging radiation directly to tumor cells while sparing surrounding healthy tissue. The market covers the full value chain from isotope production and radiopharmaceutical intermediates through to commercialized targeted alpha therapy (TAT) products, spanning oncology indications from prostate cancer to neuroendocrine tumors and select hematologic malignancies.

For procurement and strategy teams, the practical definition that matters is narrower than the scientific one: available global supply, measured in curies of clinical-grade material, still lags addressable clinical demand by a wide margin. That gap is the single most important variable driving deal-making, capital investment, and competitive positioning across this market today.

Market Snapshot

Metric

Value

Market Size (2025)

USD 685 Million

Forecast Size (2030)

USD 1,540 Million

CAGR (2025-2030)

17.6%

Base Year

2025

Forecast Period

2025-2030 (5-year)

Largest Segment (Production Method)

Thorium-229 Extraction - 48% of market

Fastest Growing Segment (Production Method)

Accelerator-Based Production - 22.4% CAGR

Largest Therapeutic Application

Prostate Cancer - 34% of demand

Largest Geography

North America - 44% of market

Fastest Growing Geography

Asia-Pacific - 20.5% CAGR

Top End User Group

Radiopharmaceutical Manufacturers - 31% of demand

Key Growth Driver

PSMA-targeted alpha therapy clinical maturation

Market Structure

Moderately consolidated (Top 3 producers: ~46% share)

Number of Major Players

8-10 global isotope producers + 15-20 therapy developers

Market Dynamics: Drivers, Restraints & Opportunities

Three forces are driving expansion. First, a maturing PSMA-targeted alpha therapy pipeline is pulling clinical-grade Ac-225 demand upward faster than headline market CAGR, as several programs approach pivotal-stage readiness. Second, accelerator-based production is scaling output efficiency, gradually easing the scarcity that has constrained the field for a decade. Third, large pharmaceutical entrants are committing capital to secure long-term supply, a signal of confidence that is itself reshaping how smaller developers negotiate access.

The dominant restraint remains production scarcity itself. Thorium-229 stockpiles are finite and geographically concentrated, and building new accelerator or reactor-based capacity requires multi-year lead times and significant capital outlay. This creates real allocation risk for developers whose trial timelines depend on guaranteed isotope access, a risk that is prompting more of the long-term supply agreements now shaping deal flow across the sector.

The clearest opportunity lies in the clinical development pipeline and regulatory pathway maturing alongside production capacity. As more programs move from investigational to clinical-use and eventually commercial-approved status, demand visibility improves, making it easier for producers to justify the capital expansion that closes the supply gap. Buyers evaluating this market should treat production-capacity roadmaps as a leading indicator of commercial timing, not a footnote to clinical data.

Actinium-225 Production & Supply Chain Landscape

Global Ac-225 supply still runs predominantly through Thorium-229 extraction, the legacy production route that yields the highest-purity material but is capped by the size of existing Thorium-229 stockpiles worldwide. Accelerator-based and cyclotron production methods are the fastest-scaling alternatives, offering a path to non-carrier-added, higher-volume output without dependence on a finite decay-chain feedstock. Reactor-assisted approaches and several emerging technologies round out a production landscape that is still consolidating around a small number of proven routes.

This production mix matters commercially because purity grade, research, clinical, or commercial, is determined largely by production method, which in turn determines which developers can even qualify a given supply source for a given trial phase. Our detailed production methods and supply technologies analysis breaks down how each route affects scalability, purity, and long-term supply reliability in far greater depth than is possible here.

MARKET SHIFT

Accelerator-based production is narrowing the historical purity gap with Thorium-229 extraction.

Producers investing early in accelerator capacity are positioning for disproportionate share gains as clinical demand scales.

This shift is prompting downstream developers to diversify supplier relationships rather than rely on a single production route.

Market Segmentation Overview

The market segments across production method, product offering, therapeutic application, development stage, end user, customer type, regulatory pathway, business model, and region, each governing a distinct commercial lens on the same underlying supply-demand story.

By product offering, direct radioisotope supply remains the largest revenue category, followed by radiopharmaceutical intermediates and contract manufacturing support, reflecting a market still weighted toward upstream isotope transactions rather than fully integrated finished-therapy sales. By therapeutic application, prostate cancer leads on the strength of PSMA-targeted programs, with neuroendocrine tumors and a cluster of solid-tumor indications following behind. On the demand side, our full spectrum of Ac-225 end users and customer segments analysis shows radiopharmaceutical manufacturers and biotechnology companies as the two largest buyer categories, though academic medical centers and government laboratories play an outsized role in early-stage demand relative to their share of overall spend.

Segment growth rates diverge meaningfully from the total market average. Solid-tumor applications outside prostate cancer are expanding faster than the market overall as developers pursue indication expansion, while commercial-grade product offerings are growing off a still-small base as the first therapies approach approval. Executives should read segment CAGR divergence as a signal of where near-term competitive intensity will concentrate, not simply as a growth league table.

Targeted Alpha Therapy: Clinical & Application Landscape

Targeted alpha therapy's clinical rationale rests on the short tissue range and high linear energy transfer of alpha particles, which allow Ac-225-labeled agents to inflict lethal, double-strand DNA damage on targeted cancer cells while limiting collateral damage to healthy tissue nearby. This mechanism has proven especially compelling in prostate cancer, where PSMA-targeted Ac-225 conjugates are the most clinically advanced application in the market, and in neuroendocrine tumors, where peptide receptor radionuclide therapy experience has created a natural adoption pathway.

Beyond these two leading indications, developers are pursuing hematologic malignancies and a widening set of solid tumors, including breast, lung, ovarian, and renal cancer. Our targeted alpha therapy applications across cancer types page maps this indication landscape in full, including which cancer types are seeing the fastest expansion in active development programs.

For manufacturers and investors, indication breadth is a double-edged signal. It demonstrates platform versatility and expands the addressable patient population, but it also multiplies the number of supply commitments a single production base must eventually support, reinforcing why capacity planning and clinical pipeline maturity have become inseparable strategic questions.

Regional Snapshot: North America, Europe & Asia-Pacific

North America holds the largest regional share of the market, underpinned by concentrated isotope production capacity, a dense cluster of clinical trial activity, and the presence of leading academic and government research institutions actively expanding domestic supply. Europe follows as the second-largest region, supported by established radiopharmaceutical manufacturing infrastructure and a growing number of accelerator-based production initiatives.

Asia-Pacific is the fastest-growing region, driven by expanding nuclear medicine infrastructure, rising government investment in domestic isotope production, and growing clinical trial participation across Japan, South Korea, China, and Australia. Latin America and the Middle East & Africa remain nascent but are attracting early-stage academic and government interest as global supply gradually diversifies beyond its historical concentration in North America and Europe.

Leading Companies in Ac-225 Supply & Alpha Therapy

The competitive landscape spans two distinct but increasingly interconnected groups: isotope producers, including NorthStar Medical Radioisotopes, ITM Isotope Technologies Munich, Eckert & Ziegler, and Orano Med, and targeted alpha therapy developers, including Bayer Radiology, Fusion Pharmaceuticals, RayzeBio, Telix Pharmaceuticals, and Curium Pharma. Strategic partnerships linking these two groups are becoming the primary mechanism through which developers secure the supply certainty their clinical programs require.

Our leading companies driving Ac-225 supply and alpha therapy development profile page provides a structured, value-chain view of this landscape, distinguishing upstream production specialists from downstream clinical developers without exposing the detailed competitive benchmarking reserved for the full report.

COMPETITIVE WATCH

Producer-developer partnerships are consolidating around a small number of preferred long-term supply relationships.

New entrants with proprietary accelerator technology are the segment most likely to disrupt current supplier concentration.

Full competitive benchmarking, including market share and strategic positioning detail, is reserved for the complete report.

Why This Report Matters

Few markets carry as tight a link between physical production constraints and clinical commercial outcomes as Ac-225. Executives making sourcing, investment, or partnership decisions in this space are effectively underwriting production-capacity risk alongside clinical-trial risk, and the two cannot be evaluated independently.

This report exists to give strategy, business development, and investment teams a single, unified view of both sides of that equation, upstream supply economics and downstream clinical demand, rather than forcing them to reconcile fragmented isotope-market data with separately sourced clinical-pipeline intelligence. Our full analysis extends into buyer intelligence, procurement dynamics, competitive benchmarking, pricing intelligence, and strategic recommendations that go well beyond what is presented here.

Frequently Asked Questions

The global Actinium-225 radiopharmaceutical supply and targeted alpha therapy market was valued at USD 685 million in 2025 and is projected to reach USD 1,540 million by 2030, growing at a CAGR of 17.6%.

Growth is driven primarily by the clinical maturation of PSMA-targeted alpha therapy in prostate cancer, expanding accelerator-based production capacity, and increasing long-term supply commitments from large pharmaceutical entrants.

Thorium-229 extraction remains the largest production method by volume, though accelerator-based production is the fastest-growing route as producers work to close the global supply gap.

North America holds the largest regional share, supported by concentrated production capacity and dense clinical trial activity, while Asia-Pacific is the fastest-growing region.

Leading isotope producers include NorthStar Medical Radioisotopes, ITM Isotope Technologies Munich, Eckert & Ziegler, and Orano Med, while leading therapy developers include Bayer Radiology, Fusion Pharmaceuticals, RayzeBio, Telix Pharmaceuticals, and Curium Pharma.

Prostate cancer, via PSMA-targeted alpha therapy, is the leading application, followed by neuroendocrine tumors and an expanding set of solid tumor indications including breast, lung, ovarian, and renal cancer.

Inquire Before Buying Request Free Sample Ask For Discount

1   Introduction

1.1   Objective of the Study

1.2   Market Definition

1.3   Market Scope

2   Executive Summary

3   Global Actinium-225 Radiopharmaceutical Supply & Targeted Alpha Therapy Market Analysis and Forecast (2026–2030)

3.1   Overview

3.2   Market Dynamics

3.3   Drivers

3.4   Restraints

3.5   Opportunities

3.6   Porters Five Force Model

3.7   Value Chain Analysis

4   Global Actinium-225 Market, By Radioisotope Type

4.1   Actinium-225

4.2   Actinium-225 Generator-Derived Products

4.3   High-Purity Ac-225 Variants

4.4   Research-Grade Ac-225

4.5   Clinical-Grade Ac-225

4.6   Commercial-Grade Ac-225

5   Global Actinium-225 Market, By Production Method

5.1   Thorium-229 Extraction

5.2   Accelerator-Based Production

5.3   Cyclotron Production

5.4   Reactor-Assisted Production

5.5   Emerging Production Technologies

6   Global Actinium-225 Market, By Product Offering

6.1   Radioisotope Supply

6.2   Radiopharmaceutical Intermediates

6.3   Alpha-Emitter Precursor Materials

6.4   Contract Manufacturing Support

6.5   Development Partnerships

6.6   Research Materials

7   Global Actinium-225 Market, By Therapeutic Application

7.1   Prostate Cancer

7.2   Neuroendocrine Tumors

7.3   Leukemia

7.4   Lymphoma

7.5   Breast Cancer

7.6   Lung Cancer

7.7   Ovarian Cancer

7.8   Renal Cancer

7.9   Other Solid Tumors

8   Global Actinium-225 Market, By Development Stage

8.1   Preclinical

8.2   Phase I

8.3   Phase II

8.4   Phase III

8.5   Commercialized Therapies

9   Global Actinium-225 Market, By End User

9.1   Radiopharmaceutical Manufacturers

9.2   Biotechnology Companies

9.3   Pharmaceutical Companies

9.4   Academic Medical Centers

9.5   Cancer Research Institutes

9.6   Nuclear Medicine Centers

9.7   Government Laboratories

10   Global Actinium-225 Market, By Customer Type

10.1   Commercial Therapy Developers

10.2   Contract Development Organizations

10.3   Research Institutions

10.4   Government-Funded Programs

10.5   Strategic Manufacturing Partners

11   Global Actinium-225 Market, By Regulatory Pathway

11.1   Investigational Applications

11.2   Clinical-Use Products

11.3   Commercial-Approved Therapies

11.4   Compassionate-Use Programs

12   Global Actinium-225 Market, By Business Model

12.1   Direct Isotope Supply

12.2   Long-Term Supply Agreements

12.3   Strategic Development Partnerships

12.4   Contract Manufacturing Arrangements

12.5   Licensing Collaborations

13   Global Actinium-225 Market, By Region

13.1   Introduction

13.2   Market Share Analysis

13.3   Market Size and Forecast

13.4   Market Size and Forecast, By Geography

14   North America Actinium-225 Market Analysis and Forecast (2026–2030)

14.1   Introduction

14.2   Market Share Analysis

14.3   Market Size and Forecast

14.4   Market Size and Forecast, By Geography

14.4.1   United States

14.4.1.1   Market Share Analysis

14.4.1.2   Market Size and Forecast

14.4.1.3   By Product

14.4.1.4   By Application

14.4.1.5   By End User

14.4.1.6   By Customer Type

14.4.1.7   Wisconsin

14.4.1.7.1   Market Share Analysis

14.4.1.7.2   Market Size and Forecast

14.4.1.7.3   By Product

14.4.1.7.4   By Application

14.4.1.7.5   By End User

14.4.1.7.6   By Customer Type

14.4.1.8   Illinois

14.4.1.8.1   Market Share Analysis

14.4.1.8.2   Market Size and Forecast

14.4.1.8.3   By Product

14.4.1.8.4   By Application

14.4.1.8.5   By End User

14.4.1.8.6   By Customer Type

14.4.1.9   Texas

14.4.1.9.1   Market Share Analysis

14.4.1.9.2   Market Size and Forecast

14.4.1.9.3   By Product

14.4.1.9.4   By Application

14.4.1.9.5   By End User

14.4.1.9.6   By Customer Type

14.4.1.10   California

14.4.1.10.1   Market Share Analysis

14.4.1.10.2   Market Size and Forecast

14.4.1.10.3   By Product

14.4.1.10.4   By Application

14.4.1.10.5   By End User

14.4.1.10.6   By Customer Type

14.4.1.11   Massachusetts

14.4.1.11.1   Market Share Analysis

14.4.1.11.2   Market Size and Forecast

14.4.1.11.3   By Product

14.4.1.11.4   By Application

14.4.1.11.5   By End User

14.4.1.11.6   By Customer Type

14.4.1.12   Pennsylvania

14.4.1.12.1   Market Share Analysis

14.4.1.12.2   Market Size and Forecast

14.4.1.12.3   By Product

14.4.1.12.4   By Application

14.4.1.12.5   By End User

14.4.1.12.6   By Customer Type

14.4.1.13   New Jersey

14.4.1.13.1   Market Share Analysis

14.4.1.13.2   Market Size and Forecast

14.4.1.13.3   By Product

14.4.1.13.4   By Application

14.4.1.13.5   By End User

14.4.1.13.6   By Customer Type

14.4.1.14   Tennessee

14.4.1.14.1   Market Share Analysis

14.4.1.14.2   Market Size and Forecast

14.4.1.14.3   By Product

14.4.1.14.4   By Application

14.4.1.14.5   By End User

14.4.1.14.6   By Customer Type

14.4.2   Canada

14.4.2.1   Market Share Analysis

14.4.2.2   Market Size and Forecast

14.4.2.3   By Product

14.4.2.4   By Application

14.4.2.5   By End User

14.4.2.6   By Customer Type

15   Europe Actinium-225 Market Analysis and Forecast (2026–2030)

15.1   Introduction

15.2   Market Share Analysis

15.3   Market Size and Forecast

15.4   Market Size and Forecast, By Geography

15.4.1   Germany

15.4.1.1   Market Share Analysis

15.4.1.2   Market Size and Forecast

15.4.1.3   By Product

15.4.1.4   By Application

15.4.1.5   By End User

15.4.1.6   By Customer Type

15.4.2   France

15.4.2.1   Market Share Analysis

15.4.2.2   Market Size and Forecast

15.4.2.3   By Product

15.4.2.4   By Application

15.4.2.5   By End User

15.4.2.6   By Customer Type

15.4.3   United Kingdom

15.4.3.1   Market Share Analysis

15.4.3.2   Market Size and Forecast

15.4.3.3   By Product

15.4.3.4   By Application

15.4.3.5   By End User

15.4.3.6   By Customer Type

15.4.4   Switzerland

15.4.4.1   Market Share Analysis

15.4.4.2   Market Size and Forecast

15.4.4.3   By Product

15.4.4.4   By Application

15.4.4.5   By End User

15.4.4.6   By Customer Type

15.4.5   Belgium

15.4.5.1   Market Share Analysis

15.4.5.2   Market Size and Forecast

15.4.5.3   By Product

15.4.5.4   By Application

15.4.5.5   By End User

15.4.5.6   By Customer Type

15.4.6   Netherlands

15.4.6.1   Market Share Analysis

15.4.6.2   Market Size and Forecast

15.4.6.3   By Product

15.4.6.4   By Application

15.4.6.5   By End User

15.4.6.6   By Customer Type

15.4.7   Italy

15.4.7.1   Market Share Analysis

15.4.7.2   Market Size and Forecast

15.4.7.3   By Product

15.4.7.4   By Application

15.4.7.5   By End User

15.4.7.6   By Customer Type

15.4.8   Spain

15.4.8.1   Market Share Analysis

15.4.8.2   Market Size and Forecast

15.4.8.3   By Product

15.4.8.4   By Application

15.4.8.5   By End User

15.4.8.6   By Customer Type

16   Asia-Pacific Actinium-225 Market Analysis and Forecast (2026–2030)

16.1   Introduction

16.2   Market Share Analysis

16.3   Market Size and Forecast

16.4   Market Size and Forecast, By Geography

16.4.1   Japan

16.4.1.1   Market Share Analysis

16.4.1.2   Market Size and Forecast

16.4.1.3   By Product

16.4.1.4   By Application

16.4.1.5   By End User

16.4.1.6   By Customer Type

16.4.2   South Korea

16.4.2.1   Market Share Analysis

16.4.2.2   Market Size and Forecast

16.4.2.3   By Product

16.4.2.4   By Application

16.4.2.5   By End User

16.4.2.6   By Customer Type

16.4.3   China

16.4.3.1   Market Share Analysis

16.4.3.2   Market Size and Forecast

16.4.3.3   By Product

16.4.3.4   By Application

16.4.3.5   By End User

16.4.3.6   By Customer Type

16.4.4   Australia

16.4.4.1   Market Share Analysis

16.4.4.2   Market Size and Forecast

16.4.4.3   By Product

16.4.4.4   By Application

16.4.4.5   By End User

16.4.4.6   By Customer Type

16.4.5   Singapore

16.4.5.1   Market Share Analysis

16.4.5.2   Market Size and Forecast

16.4.5.3   By Product

16.4.5.4   By Application

16.4.5.5   By End User

16.4.5.6   By Customer Type

17   Buyer Intelligence & Demand Landscape

17.1   Buyer Segmentation

17.2   Buyer Industries

17.3   Buyer Company Types

17.4   Country-Wise Buyer Mapping

17.5   Regional Demand Clusters

17.6   Buyer Scale Classification

17.7   Procurement Models

17.8   Buying Triggers

17.9   Decision-Maker Roles

17.10   Budget Ownership

17.11   Vendor Selection Criteria

17.12   Contract Value Bands

17.13   Sales Cycle Length

17.14   Strategic Relevance for NorthStar

18   Competition Analysis

18.1   Market Positioning Overview

18.2   Competitive Benchmarking Metrics

18.3   Strategic Moves

18.4   Competitive Mapping & Gaps

19   Company Profiles

19.1   NorthStar Medical Radioisotopes

19.1.1   Overview

19.1.2   Geographic Footprint

19.1.3   Product & Service Portfolio

19.1.4   Target Customer Segments

19.1.5   Distribution & GTM Strategy

19.1.6   Key Financials

19.1.7   Regulatory Certifications

19.1.8   Partnerships & Alliances

19.1.9   R&D and Innovation Focus

19.1.10   Recent Developments

19.1.11   SWOT Snapshot

19.2   Bayer Radiology

19.2.1   Overview

19.2.2   Geographic Footprint

19.2.3   Product & Service Portfolio

19.2.4   Target Customer Segments

19.2.5   Distribution & GTM Strategy

19.2.6   Key Financials

19.2.7   Regulatory Certifications

19.2.8   Partnerships & Alliances

19.2.9   R&D and Innovation Focus

19.2.10   Recent Developments

19.2.11   SWOT Snapshot

19.3   ITM Isotope Technologies Munich

19.3.1   Overview

19.3.2   Geographic Footprint

19.3.3   Product & Service Portfolio

19.3.4   Target Customer Segments

19.3.5   Distribution & GTM Strategy

19.3.6   Key Financials

19.3.7   Regulatory Certifications

19.3.8   Partnerships & Alliances

19.3.9   R&D and Innovation Focus

19.3.10   Recent Developments

19.3.11   SWOT Snapshot

19.4   Eckert & Ziegler

19.4.1   Overview

19.4.2   Geographic Footprint

19.4.3   Product & Service Portfolio

19.4.4   Target Customer Segments

19.4.5   Distribution & GTM Strategy

19.4.6   Key Financials

19.4.7   Regulatory Certifications

19.4.8   Partnerships & Alliances

19.4.9   R&D and Innovation Focus

19.4.10   Recent Developments

19.4.11   SWOT Snapshot

19.5   TerraPower Isotopes

19.5.1   Overview

19.5.2   Geographic Footprint

19.5.3   Product & Service Portfolio

19.5.4   Target Customer Segments

19.5.5   Distribution & GTM Strategy

19.5.6   Key Financials

19.5.7   Regulatory Certifications

19.5.8   Partnerships & Alliances

19.5.9   R&D and Innovation Focus

19.5.10   Recent Developments

19.5.11   SWOT Snapshot

19.6   RadioMedix

19.6.1   Overview

19.6.2   Geographic Footprint

19.6.3   Product & Service Portfolio

19.6.4   Target Customer Segments

19.6.5   Distribution & GTM Strategy

19.6.6   Key Financials

19.6.7   Regulatory Certifications

19.6.8   Partnerships & Alliances

19.6.9   R&D and Innovation Focus

19.6.10   Recent Developments

19.6.11   SWOT Snapshot

19.7   Orano Med

19.7.1   Overview

19.7.2   Geographic Footprint

19.7.3   Product & Service Portfolio

19.7.4   Target Customer Segments

19.7.5   Distribution & GTM Strategy

19.7.6   Key Financials

19.7.7   Regulatory Certifications

19.7.8   Partnerships & Alliances

19.7.9   R&D and Innovation Focus

19.7.10   Recent Developments

19.7.11   SWOT Snapshot

19.8   Fusion Pharmaceuticals

19.8.1   Overview

19.8.2   Geographic Footprint

19.8.3   Product & Service Portfolio

19.8.4   Target Customer Segments

19.8.5   Distribution & GTM Strategy

19.8.6   Key Financials

19.8.7   Regulatory Certifications

19.8.8   Partnerships & Alliances

19.8.9   R&D and Innovation Focus

19.8.10   Recent Developments

19.8.11   SWOT Snapshot

19.9   RayzeBio

19.9.1   Overview

19.9.2   Geographic Footprint

19.9.3   Product & Service Portfolio

19.9.4   Target Customer Segments

19.9.5   Distribution & GTM Strategy

19.9.6   Key Financials

19.9.7   Regulatory Certifications

19.9.8   Partnerships & Alliances

19.9.9   R&D and Innovation Focus

19.9.10   Recent Developments

19.9.11   SWOT Snapshot

19.10   Telix Pharmaceuticals

19.10.1   Overview

19.10.2   Geographic Footprint

19.10.3   Product & Service Portfolio

19.10.4   Target Customer Segments

19.10.5   Distribution & GTM Strategy

19.10.6   Key Financials

19.10.7   Regulatory Certifications

19.10.8   Partnerships & Alliances

19.10.9   R&D and Innovation Focus

19.10.10   Recent Developments

19.10.11   SWOT Snapshot

19.11   Curium Pharma

19.11.1   Overview

19.11.2   Geographic Footprint

19.11.3   Product & Service Portfolio

19.11.4   Target Customer Segments

19.11.5   Distribution & GTM Strategy

19.11.6   Key Financials

19.11.7   Regulatory Certifications

19.11.8   Partnerships & Alliances

19.11.9   R&D and Innovation Focus

19.11.10   Recent Developments

19.11.11   SWOT Snapshot

19.12   NRG PALLAS

19.12.1   Overview

19.12.2   Geographic Footprint

19.12.3   Product & Service Portfolio

19.12.4   Target Customer Segments

19.12.5   Distribution & GTM Strategy

19.12.6   Key Financials

19.12.7   Regulatory Certifications

19.12.8   Partnerships & Alliances

19.12.9   R&D and Innovation Focus

19.12.10   Recent Developments

19.12.11   SWOT Snapshot

19.13   PanTera

19.13.1   Overview

19.13.2   Geographic Footprint

19.13.3   Product & Service Portfolio

19.13.4   Target Customer Segments

19.13.5   Distribution & GTM Strategy

19.13.6   Key Financials

19.13.7   Regulatory Certifications

19.13.8   Partnerships & Alliances

19.13.9   R&D and Innovation Focus

19.13.10   Recent Developments

19.13.11   SWOT Snapshot

19.14   Actinium Pharmaceuticals

19.14.1   Overview

19.14.2   Geographic Footprint

19.14.3   Product & Service Portfolio

19.14.4   Target Customer Segments

19.14.5   Distribution & GTM Strategy

19.14.6   Key Financials

19.14.7   Regulatory Certifications

19.14.8   Partnerships & Alliances

19.14.9   R&D and Innovation Focus

19.14.10   Recent Developments

19.14.11   SWOT Snapshot

19.15   Alpha Tau Medical

19.15.1   Overview

19.15.2   Geographic Footprint

19.15.3   Product & Service Portfolio

19.15.4   Target Customer Segments

19.15.5   Distribution & GTM Strategy

19.15.6   Key Financials

19.15.7   Regulatory Certifications

19.15.8   Partnerships & Alliances

19.15.9   R&D and Innovation Focus

19.15.10   Recent Developments

19.15.11   SWOT Snapshot

19.16   Nusano

19.16.1   Overview

19.16.2   Geographic Footprint

19.16.3   Product & Service Portfolio

19.16.4   Target Customer Segments

19.16.5   Distribution & GTM Strategy

19.16.6   Key Financials

19.16.7   Regulatory Certifications

19.16.8   Partnerships & Alliances

19.16.9   R&D and Innovation Focus

19.16.10   Recent Developments

19.16.11   SWOT Snapshot

19.17   ARTBIO

19.17.1   Overview

19.17.2   Geographic Footprint

19.17.3   Product & Service Portfolio

19.17.4   Target Customer Segments

19.17.5   Distribution & GTM Strategy

19.17.6   Key Financials

19.17.7   Regulatory Certifications

19.17.8   Partnerships & Alliances

19.17.9   R&D and Innovation Focus

19.17.10   Recent Developments

19.17.11   SWOT Snapshot

19.18   POINT Biopharma

19.18.1   Overview

19.18.2   Geographic Footprint

19.18.3   Product & Service Portfolio

19.18.4   Target Customer Segments

19.18.5   Distribution & GTM Strategy

19.18.6   Key Financials

19.18.7   Regulatory Certifications

19.18.8   Partnerships & Alliances

19.18.9   R&D and Innovation Focus

19.18.10   Recent Developments

19.18.11   SWOT Snapshot

Frequently Asked Questions

The global Actinium-225 radiopharmaceutical supply and targeted alpha therapy market was valued at USD 685 million in 2025 and is projected to reach USD 1,540 million by 2030, growing at a CAGR of 17.6%.

Growth is driven primarily by the clinical maturation of PSMA-targeted alpha therapy in prostate cancer, expanding accelerator-based production capacity, and increasing long-term supply commitments from large pharmaceutical entrants.

Thorium-229 extraction remains the largest production method by volume, though accelerator-based production is the fastest-growing route as producers work to close the global supply gap.

North America holds the largest regional share, supported by concentrated production capacity and dense clinical trial activity, while Asia-Pacific is the fastest-growing region.

Leading isotope producers include NorthStar Medical Radioisotopes, ITM Isotope Technologies Munich, Eckert & Ziegler, and Orano Med, while leading therapy developers include Bayer Radiology, Fusion Pharmaceuticals, RayzeBio, Telix Pharmaceuticals, and Curium Pharma.

Prostate cancer, via PSMA-targeted alpha therapy, is the leading application, followed by neuroendocrine tumors and an expanding set of solid tumor indications including breast, lung, ovarian, and renal cancer.

Inquire Before Buying Request Free Sample Ask For Discount

Research Methodology

Base-year market sizing was developed through a multi-layer triangulation process rather than reliance on any single source.

Public Market Forecasts

Multiple independently published market estimates for Actinium-225 and the closely adjacent alpha-emitter category were cross-referenced to establish a defensible base-year range before narrowing to a central estimate specific to this report's scope.

Adjacent-Market Disclosures

Radioligand therapy and radiotheranostics category disclosures, along with isotope producer capacity announcements, were used as upper- and lower-bound cross-checks against the direct Ac-225 estimates, ensuring the final figure reflects genuine scope alignment rather than a mismatched proxy.

Segment-Share Derivation

Production method, therapeutic application, and end-user shares were derived by applying documented differentials, such as relative clinical trial concentration by indication and known production-route capacity constraints, to the triangulated base estimate, with all segment shares validated to sum to 100%.

Regional Cross-Check

Regional shares were checked against independently published regional breakdowns for adjacent alpha-emitter and radioligand therapy categories, then adjusted to reflect this report's precise Ac-225 supply-and-therapy scope.

Frequently Asked Questions

The global Actinium-225 radiopharmaceutical supply and targeted alpha therapy market was valued at USD 685 million in 2025 and is projected to reach USD 1,540 million by 2030, growing at a CAGR of 17.6%.

Growth is driven primarily by the clinical maturation of PSMA-targeted alpha therapy in prostate cancer, expanding accelerator-based production capacity, and increasing long-term supply commitments from large pharmaceutical entrants.

Thorium-229 extraction remains the largest production method by volume, though accelerator-based production is the fastest-growing route as producers work to close the global supply gap.

North America holds the largest regional share, supported by concentrated production capacity and dense clinical trial activity, while Asia-Pacific is the fastest-growing region.

Leading isotope producers include NorthStar Medical Radioisotopes, ITM Isotope Technologies Munich, Eckert & Ziegler, and Orano Med, while leading therapy developers include Bayer Radiology, Fusion Pharmaceuticals, RayzeBio, Telix Pharmaceuticals, and Curium Pharma.

Prostate cancer, via PSMA-targeted alpha therapy, is the leading application, followed by neuroendocrine tumors and an expanding set of solid tumor indications including breast, lung, ovarian, and renal cancer.

Inquire Before Buying Request Free Sample Ask For Discount